GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (OTCPK:ENTBF) » Definitions » Short Interest

Entheon Biomedical (Entheon Biomedical) Short Interest


View and export this data going back to 2020. Start your Free Trial

What is Entheon Biomedical Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Entheon Biomedical's Short Interest

For the Biotechnology subindustry, Entheon Biomedical's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entheon Biomedical's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entheon Biomedical's Short Interest distribution charts can be found below:

* The bar in red indicates where Entheon Biomedical's Short Interest falls into.


Entheon Biomedical (Entheon Biomedical) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (OTCPK:ENTBF) » Definitions » Short Interest
Comparable Companies
XCNQ:MYND XCNQ:ABRT XCNQ:WESA.X TSXV:BTI XCNQ:HAVN TSXV:IBO XCNQ:GTTX TSXV:APC.H XCNQ:MOOD XCNQ:NSHS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
1XU1:Germany ENBI:Canada
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Website
https://www.entheonbiomedical.com
Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.